Behcet Disease – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Behcet Disease – Pipeline Review, H2 2016’, provides an overview of the Behcet Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Behcet Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Behcet Disease

The report reviews pipeline therapeutics for Behcet Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Behcet Disease therapeutics and enlists all their major and minor projects

The report assesses Behcet Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Behcet Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Behcet Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Behcet Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Celgene Corp

Cell Medica Ltd

Coherus BioSciences Inc

Genor BioPharma Co Ltd

Iltoo Pharma

Mycenax Biotech Inc

Novartis AG

Panacea Biotec Ltd

R Pharm

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Behcet Disease Overview 7

Therapeutics Development 8

Pipeline Products for Behcet Disease - Overview 8

Pipeline Products for Behcet Disease - Comparative Analysis 9

Behcet Disease - Therapeutics under Development by Companies 10

Behcet Disease - Therapeutics under Investigation by Universities/Institutes 11

Behcet Disease - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Unknown Stage Products 15

Behcet Disease - Products under Development by Companies 16

Behcet Disease - Products under Investigation by Universities/Institutes 17

Behcet Disease - Companies Involved in Therapeutics Development 18

AbbVie Inc 18

Celgene Corp 19

Cell Medica Ltd 20

Coherus BioSciences Inc 21

Genor BioPharma Co Ltd 22

Iltoo Pharma 23

Mycenax Biotech Inc 24

Novartis AG 25

Panacea Biotec Ltd 26

R Pharm 27

Behcet Disease - Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

adalimumab - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

adalimumab biosimilar - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

adalimumab biosimilar - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

adalimumab biosimilar - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

adalimumab biosimilar - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

aldesleukin - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

apremilast - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

canakinumab - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

DLX-105 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

infliximab biosimilar - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

pentoxifylline - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

RPH-104 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Behcet Disease - Dormant Projects 72

Behcet Disease - Discontinued Products 73

Behcet Disease - Product Development Milestones 74

Featured News & Press Releases 74

Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 74

Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 75

Apr 15, 2015: Phase II Data for Apremilast in Behcet’s Disease Published in The New England Journal of Medicine 75

Apr 14, 2015: Delenex Announces New Clinical Data 77

Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet’s Disease At EULAR 77

May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet Disease For Humira Pre-filled Syringe In Japan 78

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

List of Tables

Number of Products under Development for Behcet Disease, H2 2016 8

Number of Products under Development for Behcet Disease – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Comparative Analysis by Unknown Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Behcet Disease – Pipeline by AbbVie Inc, H2 2016 18

Behcet Disease – Pipeline by Celgene Corp, H2 2016 19

Behcet Disease – Pipeline by Cell Medica Ltd, H2 2016 20

Behcet Disease – Pipeline by Coherus BioSciences Inc, H2 2016 21

Behcet Disease – Pipeline by Genor BioPharma Co Ltd, H2 2016 22

Behcet Disease – Pipeline by Iltoo Pharma, H2 2016 23

Behcet Disease – Pipeline by Mycenax Biotech Inc, H2 2016 24

Behcet Disease – Pipeline by Novartis AG, H2 2016 25

Behcet Disease – Pipeline by Panacea Biotec Ltd, H2 2016 26

Behcet Disease – Pipeline by R Pharm, H2 2016 27

Assessment by Monotherapy Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 32

Number of Products by Stage and Route of Administration, H2 2016 34

Number of Products by Stage and Molecule Type, H2 2016 36

Behcet Disease – Dormant Projects, H2 2016 72

Behcet Disease – Discontinued Products, H2 2016 73

List of Figures

List of Figures

Number of Products under Development for Behcet Disease, H2 2016 8

Number of Products under Development for Behcet Disease – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 28

Number of Products by Targets, H2 2016 29

Number of Products by Stage and Targets, H2 2016 29

Number of Products by Mechanism of Actions, H2 2016 31

Number of Products by Stage and Mechanism of Actions, H2 2016 31

Number of Products by Routes of Administration, H2 2016 33

Number of Products by Stage and Routes of Administration, H2 2016 33

Number of Products by Molecule Types, H2 2016 35

Number of Products by Stage and Molecule Types, H2 2016 35

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports